Davunetide

Overview

Davunetide, also known by the laboratory designation NAP, is an eight-amino-acid peptide fragment (NAPVSIPQ) derived from activity-dependent neuroprotective protein, or ADNP. ADNP is essential for normal brain development, and researchers identified the NAP fragment as the smallest segment that appeared to retain the parent protein's neuroprotective activity in laboratory models. Because of this, davunetide was advanced as an experimental candidate for neurodegenerative and neurodevelopmental conditions.

It is important to state clearly that davunetide is not an approved drug anywhere in the world. It was studied in human clinical trials but did not demonstrate the benefits its developers had hoped for. The peptide remains a subject of academic research rather than a treatment, and any material sold under this name is an unapproved research chemical.

Davunetide is often discussed in the context of tauopathies, a family of disorders in which the protein tau accumulates abnormally inside neurons. The scientific interest centered on whether stabilizing the internal scaffolding of nerve cells could slow this process.

How it works

The proposed mechanism of davunetide centers on microtubules, the protein filaments that form part of a cell's internal skeleton. In neurons, microtubules are critical for transporting cargo along the length of axons and for maintaining cell structure. The protein tau normally helps stabilize these microtubules, and in tauopathies this stabilizing function is disrupted.

In preclinical studies, davunetide appeared to support microtubule stability and to interact with proteins involved in microtubule assembly. Researchers hypothesized that by reinforcing this scaffolding, the peptide might protect neurons from the structural breakdown seen in degenerative disease and might reduce abnormal tau-related changes.

It is worth emphasizing that much of this mechanistic understanding comes from cell culture and animal experiments. Mechanisms that look promising in the laboratory frequently fail to translate into measurable clinical benefit, and davunetide ultimately became an example of this gap. The biological rationale was plausible, but a plausible mechanism is not the same as a proven therapeutic effect in people.

Research & evidence

Davunetide reached relatively advanced human testing. Its most prominent evaluation was a large phase 2/3 trial in progressive supranuclear palsy, a rare and aggressive tauopathy that affects movement, balance, and cognition. This study is the central piece of clinical evidence and is the reason davunetide is frequently cited as a cautionary case.

The trial did not meet its primary endpoints. Davunetide failed to slow the progression of progressive supranuclear palsy compared with placebo, and the program was discontinued. Earlier exploratory work had also examined the peptide in other contexts, including cognitive and psychiatric research, but none of these efforts produced approval or established efficacy.

The honest summary is that davunetide has been tested and has not shown clinical benefit for its main investigated indication. This negative result is scientifically valuable because it was generated through a well-conducted trial, but it means there is no evidence base supporting davunetide as an effective neuroprotective treatment. Claims that it preserves memory or protects the brain in humans are not supported by the completed research.

Safety & legal status

In the clinical trials conducted, davunetide was generally described as reasonably tolerated, and it was at one stage explored using an intranasal route of administration. However, tolerability in a monitored trial setting does not establish long-term safety, and because the drug failed and development stopped, there is no comprehensive safety profile of the kind that accompanies approved medicines.

Davunetide is not approved by the FDA, the EMA, or any other major regulator. It has no recognized medical use. Material marketed online as davunetide is sold as a research chemical and is not manufactured, tested, or labeled to pharmaceutical standards, which introduces real risks around purity, identity, and contamination.

Anyone encountering davunetide should understand that it is an experimental compound that did not succeed in trials. It should not be regarded as a viable nootropic or neuroprotective agent, and self-experimentation with unapproved peptides carries unknown hazards. Concerns about cognition or neurodegenerative disease should be directed to a qualified healthcare professional rather than addressed with research chemicals.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014. Peer-reviewed study
2. Gozes I. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011. Peer-reviewed study
3. Galushkin A, Gozes I. Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity. Adv Drug Deliv Rev. 2025. Peer-reviewed study
4. Morimoto BH, Fox AW, Stewart AJ, et al. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases. Expert Rev Clin Pharmacol. 2013. Peer-reviewed study
5. Gozes I, Blatt J, Lobyntseva A. Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease. Transl Psychiatry. 2024. Peer-reviewed study
6. Magen I, Gozes I. Davunetide: Peptide therapeutic in neurological disorders. Curr Med Chem. 2014. Peer-reviewed study